Filing Analysis
Beyond Air, Inc. filed an 8-K to announce its financial results for the fiscal quarter ended June 30, 2026, and to provide updates on recent corporate developments via a press release.
📋 Key Facts
- The filing reports results of operations and financial condition for the quarter ended June 30, 2026.
- The company issued a press release on August 13, 2026, containing the financial results.
- The report was signed by CFO Daniel Moorhead on August 18, 2026.
Beyond Air, Inc. has regained compliance with Nasdaq's minimum bid price requirement following a 1-for-20 reverse stock split. However, the company is now under a one-year 'Discretionary Panel Monitor' period, during which any further non-compliance will result in immediate delisting proceedings without the option for a compliance plan.
🚩 Red Flags
- Imposition of a Discretionary Panel Monitor (high risk of immediate delisting if any other rule is violated).
- Recent 1-for-20 reverse stock split used to artificially meet minimum bid requirements.
- Loss of the ability to submit compliance plans for new deficiencies during the monitor period.
📋 Key Facts
- Company regained compliance with Nasdaq Bid Price Rule (5550(a)(2)) as of August 6, 2026.
- Compliance was achieved after a 1-for-20 reverse stock split executed on July 13, 2026.
- The company maintained a closing bid price at or above $1.00 for 17 consecutive trading days (July 13 to August 4, 2026).
- Nasdaq has imposed a one-year 'Discretionary Panel Monitor' period starting from the date of the Compliance Letter.
- During the monitor period, the company is prohibited from submitting compliance plans for any new deficiencies.
Beyond Air, Inc. entered into a securities purchase agreement for a private placement of common stock and various warrants totaling approximately $10.2 million in gross proceeds. The offering includes participation from company directors and executive officers.
🚩 Red Flags
- Related-party transaction: Company directors and executive officers (including CEO Robert Goodman and CFO Daniel Moorhead) are participating in the private placement.
- Significant dilution potential: The offering includes a large number of warrants (up to 1.6M Pre-Funded, 1.8M Series A, and 1.8M Series B), which could lead to substantial share dilution upon exercise.
- Variable Rate Transaction restrictions: The company is restricted from certain equity issuances/ATM facilities for up to 180 days following the effectiveness of the registration statement.
📋 Key Facts
- Private placement of 167,011 shares of common stock and associated Pre-Funded Warrants, Series A Warrants, and Series B Warrants.
- Gross proceeds expected to be approximately $10.2 million at closing (expected ~July 31, 2026).
- Combined purchase price for Shares/Warrants: $5.66 for institutional investors; $5.76 for directors and executive officers.
- Pre-Funded Warrants have an exercise price of $0.0001 per share.
- Series A and Series B Warrants have an exercise price of $5.51 per share.
- The company is obligated to pay a 7.0% cash fee (~$0.7 million) to placement agents (Cantor, Citizens JMP, Lake Street).
- Includes a registration rights agreement requiring the filing of a resale registration statement within 15 days of closing.
Beyond Air, Inc. has approved a 1-for-20 reverse stock split to regain compliance with Nasdaq's minimum bid price requirement of $1.00 per share.
🚩 Red Flags
- Reverse stock split (often a sign of extreme share price depreciation).
- Nasdaq delisting risk/non-compliance with minimum bid price requirements.
- Company explicitly states it cannot guarantee the split will achieve or sustain compliance.
📋 Key Facts
- Reverse stock split ratio is 1-for-20.
- Effective date for the split is July 13, 2026, at 12:01 a.m. ET.
- The split aims to address non-compliance with Nasdaq Listing Rule 5550(a)(2).
- New CUSIP number will be 08862L301; ticker symbol 'XAIR' remains the same.
- Fractional shares will be rounded up at the participant level and no cash in lieu of fractional shares will be paid.
Beyond Air, Inc. announced its fiscal year-end change and released financial results for the period ended March 31, 2026. The company is transitioning its fiscal year from a March 31 year-end to a December 31 year-end.
📋 Key Facts
- Board of Directors approved changing the fiscal year-end from March 31 to December 31, effective December 31, 2026.
- The company will report a nine-month transition period from April 1, 2026, through December 31, 2026.
- Financial results for the fiscal quarter and year ended March 31, 2026, were released via press release on June 26, 2026.
Beyond Air, Inc. stockholders have approved a reverse stock split to address Nasdaq compliance issues. The Board has selected a 1-for-20 ratio to attempt to raise the share price above $1.00.
🚩 Red Flags
- Reverse stock split implementation is a common sign of distress in micro-cap companies.
- Imminent Nasdaq delisting risk: The company must meet the $1.00 minimum bid price requirement by July 31, 2026.
📋 Key Facts
- Stockholders approved authority for a reverse stock split between 1-for-2 and 1-for-20.
- The Board has officially selected a 1-for-20 ratio.
- The primary objective is to comply with Nasdaq Listing Rule 5550(a)(2) (the 'Bid Price Rule').
- The company must demonstrate compliance by July 31, 2026.
- The split will combine every 20 shares into one share.
Beyond Air, Inc. has received a conditional approval from the Nasdaq Hearings Panel to continue its listing, provided it regains compliance with the Bid Price Rule by July 31, 2026.
🚩 Red Flags
- The company is currently in violation of the Bid Price Rule.
- The window for compliance is very short (deadline of July 31, 2026).
- The 'Discretionary Panel Monitor' status creates a 'zero-tolerance' environment where any future deficiency leads to immediate delisting.
📋 Key Facts
- The company was non-compliant with Nasdaq Listing Rule 5550(a)(2) (the Bid Price Rule).
- The Nasdaq Hearings Panel granted a request for continued listing subject to conditions following a May 14, 2026 hearing.
- The deadline to demonstrate compliance with the Bid Price Rule is July 31, 2026.
- The company will be subject to a Discretionary Panel Monitor for one year after regaining compliance.
- Failure to meet any listing standard during the one-year monitoring period will result in a prompt written determination to delist without the option to provide a compliance plan.
Beyond Air, Inc. has requested a hearing with the Nasdaq Hearings Panel to appeal a delisting notice received on April 10, 2026, due to non-compliance with the $1.00 minimum bid price requirement. The delisting process is stayed until the hearing, currently scheduled for May 14, 2026.
🚩 Red Flags
- Failure to maintain the $1.00 minimum bid price requirement.
- Potential delisting from The Nasdaq Stock Market LLC.
- No assurance that the Panel will grant continued listing or that the company can regain compliance.
📋 Key Facts
- Received written notice from Nasdaq on April 10, 2026, for non-compliance with Rule 5550(a)(2) ($1.00 bid price).
- Timely requested a hearing before the Nasdaq Hearings Panel on April 13, 2026.
- The hearing is scheduled for May 14, 2026.
- The delisting action is stayed pending a written decision from the Panel.
- Common stock (XAIR) continues to be listed on Nasdaq during the appeal process.
Beyond Air received a Nasdaq delisting notice on April 7, 2026, for failing to maintain the $1.00 minimum bid price. Uniquely, the company is ineligible for the standard 180-day compliance period because it already executed a 1-for-20 reverse stock split within the preceding 12-month period.
🚩 Red Flags
- Immediate delisting risk without the standard 180-day compliance window.
- Failure of a previous 1-for-20 reverse split (July 2025) to maintain the stock price above $1.00 for even one year.
- Potential for a second reverse stock split within a 12-month period, which often signals chronic value erosion.
📋 Key Facts
- Received Nasdaq notice on April 7, 2026, regarding failure to satisfy the $1.00 minimum bid price rule (Rule 5550(a)(2)).
- The bid price was below $1.00 for 30 consecutive business days from February 23, 2026, to April 6, 2026.
- Ineligible for the typical 180-day grace period due to a 1-for-20 reverse stock split effected on July 14, 2025.
- Must request a hearing before the Nasdaq Hearings Panel by April 14, 2026, to stay the delisting.
- Management is considering another reverse stock split as a remedy to regain compliance.
Beyond Air, Inc. announced that Steven A. Lisi has resigned as CEO and Director, effective March 27, 2026. The company has appointed Robert Goodman, the current Chief Commercial Officer and a board member, as the new CEO.
🚩 Red Flags
- Full acceleration of all unvested equity awards for the departing CEO.
- The company has not yet finalized a compensation arrangement or employment agreement with the new CEO.
📋 Key Facts
- Steven A. Lisi resigned as CEO and Director effective March 27, 2026; the company states there were no disagreements.
- Robert Goodman, previously Chief Commercial Officer since November 2025, was appointed CEO effective March 27, 2026.
- Mr. Lisi will receive $650,000 in separation pay (12 months of base salary) and 12 months of COBRA premiums.
- All of Mr. Lisi's unvested options and restricted stock units (RSUs) will be fully accelerated and remain exercisable for 24 months.
- New CEO Robert Goodman has over 25 years of experience, including roles at Pfizer, Thermo Fisher Scientific, and BioTelemetry.
Beyond Air, Inc. filed an 8-K to announce its third quarter financial results for the period ended December 31, 2025, and provided various corporate updates via a press release.
📋 Key Facts
- Report date: February 13, 2026
- Reporting period: Third Quarter ended December 31, 2025
- The filing includes an earnings press release as Exhibit 99.1
- The company is listed on the Nasdaq Stock Market under ticker XAIR
Beyond Air, Inc. held its 2026 Annual Meeting of Stockholders on January 30, 2026. The meeting resulted in the election of six directors and the ratification of the company's independent auditor.
🚩 Red Flags
- None identified in this filing.
📋 Key Facts
- Annual Meeting held on January 30, 2026.
- Quorum was established with 4,221,408 shares (52.70% of outstanding shares) represented in person or by proxy.
- Six directors were elected to serve until the next annual meeting: Steven A. Lisi, Robert S. Goodman, Robert F. Carey, Dr. William Forbes, Yoori Lee, and Erick J. Lucera.
- Stockholders ratified the appointment of WithumSmith+Brown, PC as independent registered public accounting firm for fiscal year ending March 31, 2026.
- The Eighth Amended and Restated 2013 Equity Incentive Plan was approved, increasing reserved shares by 850,000.
Beyond Air, Inc. entered into a $5 million private placement agreement with an institutional investor involving the sale of common stock and warrants. The deal includes significant pre-funded and common warrants that could lead to substantial dilution upon exercise.
🚩 Red Flags
- Significant potential dilution from over 7 million total warrants (Pre-funded and Common)
- Pre-funded warrants have a near-zero exercise price ($0.0001), effectively acting as equity at issuance
- The company is obligated to pay liquidated damages if the registration statement is not declared effective within specified timeframes
- Standstill/Restriction: Company is prohibited from issuing other common stock or filing new registration statements for 90 days post-signing
📋 Key Facts
- Total gross proceeds: $5,000,000
- Common Stock sold: 524,990 shares at $1.272 per share
- Pre-funded Warrants issued: up to 3,405,828 shares at $1.2719 per warrant (exercise price $0.0001)
- Common Warrants issued: up to 3,930,818 shares with an exercise price of $1.147
- The offering closed on January 16, 2026
- Placement agent fee: 7.0% of gross proceeds plus expenses up to $50,000
- Registration Statement for resale is required by February 4, 2026
Beyond Air, Inc. announced a binding letter of intent for XTL Biopharmaceuticals Ltd. to acquire the company's 85% ownership interest in NeuroNOS Ltd. The transaction includes equity, cash, and significant milestone payments.
🚩 Red Flags
- Divestiture of a significant asset/subsidiary interest may indicate a shift in corporate strategy or a need for liquidity.
📋 Key Facts
- XTL Biopharmaceuticals (NASDAQ: XTLB) entered into a binding LOI to acquire 85% of NeuroNOS Ltd.
- Consideration for the 85% stake includes 19.9% of XTL's issued share capital, $1 million in cash, and up to $31.5 million in milestone-based contingent payments.
- NeuroNOS is a biotechnology company focusing on therapeutics for Autism Spectrum Disorder (ASD) and neuro-oncology.
- The transaction is currently at the LOI stage; definitive agreements are pending.
Beyond Air, Inc. announced the appointment of Daniel Moorhead as Chief Financial Officer, effective January 5, 2026. He will succeed Denton “Duke” Dewrell, who will remain with the company in the role of controller.
🚩 Red Flags
- Succession of a CFO can sometimes indicate internal turbulence, though here it appears to be a planned transition from an interim/temporary arrangement.
📋 Key Facts
- Daniel Moorhead appointed CFO, principal financial officer, and principal accounting officer effective Jan 5, 2026.
- Moorhead's annual salary is set at $325,000.
- Moorhead received an inducement stock option award for 70,000 shares of Common Stock.
- The options vest in four installments: 25% on the first anniversary and then annually in three equal installments.
- Denton “Duke” Dewrell will transition from temporary PFO/PAO duties to remain as Controller.
Beyond Air, Inc. announced the appointment of Denton 'Duke' Dewrell as Principal Financial Officer (PFO) and Principal Accounting Officer (PAO), effective December 8, 2025.
📋 Key Facts
- Denton 'Duke' Dewrell appointed as PFO and PAO on December 8, 2025.
- Mr. Dewrell previously served as the Company's Global Controller since April 2025.
- His prior experience includes serving as U.S. Controller for Beyond Air and Head of Finance/Controller at subsidiary Beyond Cancer Ltd.
- He has over ten years of public accounting experience at Ernst & Young LLP (EY).
- Annual base compensation remains unchanged at $260,000 per year.
Beyond Air, Inc. announced the resignation of its Chief Financial Officer, Doug Larson, effective December 5, 2025. The company stated the departure is not due to any disagreements regarding financial statements or internal controls.
🚩 Red Flags
- Sudden departure of a key C-suite executive (CFO) can sometimes signal underlying operational stress, though not indicated here.
📋 Key Facts
- Doug Larson resigned as CFO on November 21, 2025.
- Resignation is effective December 5, 2025.
- Larson will serve in an advisory role through the end of calendar year 2025.
- The company explicitly stated the departure is not due to disagreements regarding financial reporting or internal controls.
Beyond Air, Inc. filed an 8-K to announce the release of its financial results for the second quarter ended September 30, 2025.
📋 Key Facts
- The filing is a standard announcement of quarterly earnings (Q2 2025).
- Reporting date of earliest event: November 10, 2025.
- Financial results were released via press release on November 10, 2025.
Beyond Air, Inc. entered into a highly dilutive $20M equity purchase agreement and a $12.05M secured promissory note with Streeterville Capital, LLC. The filing also details significant related-party debt restructuring and a massive stock option repricing for executives and directors.
🚩 Red Flags
- Highly dilutive financing: The equity purchase agreement allows Streeterville to put shares at a 4% discount to VWAP or an 85% discount to Nasdaq minimum price.
- Predatory debt terms: The Note includes 'Trigger Effects' where the principal increases by 9% for Major Trigger Events and 4% for Minor Trigger Events.
- Immediate cash collateral requirement: $6,000,000 of the note proceeds were immediately sent to a controlled deposit account (DACA).
- Related-party transactions: The CEO and a Director are acting as lenders and receiving new warrants/repriced options.
- Massive option repricing: 726,618 options were repriced from significantly out-of-the-money levels ($5.89-$10.80) to $1.95, benefiting insiders at the expense of existing shareholders.
📋 Key Facts
- Entered into an Equity Purchase Agreement with Streeterville Capital for up to $20 million in common stock.
- Closed a secured promissory note with Streeterville Capital for $12,050,000 at 15% interest (first 12 months interest-free).
- The Note includes a 'monitoring fee' if the company cannot meet specific volume or market cap thresholds.
- Amended and restated loan with CEO Steven Lisi and Director Robert Carey to provide an additional $2,000,000 term loan.
- Issued supplemental warrants to Director Robert Carey for 512,821 shares at a $1.95 exercise price.
- Board approved a one-time repricing of 726,618 stock options for officers and directors, reducing exercise prices from as high as $10.80 down to $1.95.
Beyond Air, Inc. entered into an inducement agreement with 9 warrant holders to encourage the immediate exercise of existing warrants at a reduced price of $2.21 per share. In exchange for this cash infusion, the company is issuing new unregistered warrants to the holders.
🚩 Red Flags
- Dilutive event: Issuance of new warrants and immediate conversion of existing ones increases share count.
- Reduced exercise price: The company is incentivizing holders to exercise at a lower cost, likely to secure immediate liquidity.
- Unregistered securities: New Warrants are being issued under Section 4(a)(2) and Regulation D (unregistered).
- Potential for significant selling pressure: A Resale Registration Statement is required by Sept 29, 2025, which often leads to immediate market supply.
📋 Key Facts
- 9 holders agreed to exercise Existing Warrants for up to 1,439,126 shares of common stock at a reduced price of $2.21 per share.
- Gross proceeds from the exercise are approximately $3.18 million (before fees and expenses).
- The company will issue New Warrants to purchase up to 719,561 shares of common stock at an exercise price of $2.21 per share.
- New Warrants have a five-year term and are immediately exercisable.
- Laidlaw & Company (UK) Ltd. is acting as the placement agent with a 6.5% fee on gross proceeds plus up to $50,000 in legal expense reimbursement.
- The company must file a Resale Registration Statement for the New Warrants by September 29, 2025.
Beyond Air, Inc. announced that its subsidiary, NeuroNOS Limited, has received FDA Orphan Drug Designation (ODD) for its lead investigational therapy, BA-101, intended for the treatment of Glioblastoma (GBM). This is a regulatory milestone for the company's pipeline.
📋 Key Facts
- NeuroNOS Limited (a subsidiary of Beyond Air Ireland Limited) granted Orphan Drug Designation by the FDA.
- The designation applies to BA-101, the lead investigational therapy.
- Target indication: Glioblastoma (GBM).
- Filing date: September 8, 2025.
Beyond Air, Inc. filed an 8-K to announce its financial results for the first quarter ended June 30, 2025. The filing serves as a formal announcement of the earnings release issued on August 12, 2025.
📋 Key Facts
- Reporting period: First quarter ended June 30, 2025.
- Press release date: August 12, 2025.
- Filing date: August 18, 2025.
- The filing includes Exhibit 99.1 containing the earnings press release.
Beyond Air, Inc. has approved a 1-for-20 reverse stock split to regain compliance with Nasdaq's minimum bid price requirement. The split is scheduled to become effective on July 14, 2025.
🚩 Red Flags
- Reverse stock split (often associated with declining share prices and potential delisting risk).
- Explicit mention of non-compliance with Nasdaq Listing Rule 5550(a)(2) regarding the $1.00 minimum bid price.
📋 Key Facts
- Reverse stock split ratio: 1-for-20.
- Effective Date: July 14, 2025, at 12:01 a.m. ET.
- Purpose: To raise the per share bid price above $1.00 to comply with Nasdaq Listing Rule 5550(a)(2).
- New CUSIP number for Common Stock: 08862L202.
- Fractional shares will be rounded up at the participant level; no cash in lieu of fractional shares will be paid.
Beyond Air, Inc. held a special meeting of stockholders on June 20, 2025, where shareholders approved a proposal to authorize the Board to execute a reverse stock split.
🚩 Red Flags
- Approval of a reverse stock split is often used to combat low share prices and maintain Nasdaq listing compliance.
- The wide range of the potential split (up to 1-for-50) indicates significant volatility or uncertainty regarding the required price correction.
📋 Key Facts
- The Special Meeting was held on June 20, 2025.
- Stockholders approved a reverse stock split ratio between 1-for-10 and 1-for-50.
- The Board of Directors has sole discretion to determine the final ratio prior to the one-year anniversary of the Special Meeting.
- 48,476,717 shares were present at the meeting, constituting a quorum.
- Voting results for the split: 41,924,612 For; 6,382,862 Against; 169,243 Abstain.
Beyond Air, Inc. announced the appointment of Robert Goodman to its Board of Directors and reported the submission of a PMA supplement application to the FDA for LungFit PH II.
📋 Key Facts
- Appointed Robert Goodman as an independent director on June 16, 2025.
- Mr. Goodman has leadership experience at Philips Healthcare, Thermo Fisher Scientific, and Pfizer.
- Submitted a premarket approval (PMA) supplement application to the FDA for LungFit PH II (next-generation therapeutic nitric oxide generator).
- Released financial results for the fiscal quarter and year ended March 31, 2025.
Beyond Air, Inc. announced a subscription agreement for its subsidiary, NeuroNos Limited, to issue ordinary shares to investors. The transaction aims to raise up to $5 million in gross proceeds through multiple closings.
🚩 Red Flags
- Equity dilution within the subsidiary structure.
- The use of a subscription agreement for a subsidiary often indicates a need for immediate liquidity to fund specific R&D or operational milestones.
📋 Key Facts
- NeuroNos Limited (a wholly owned subsidiary of Beyond Air Ireland Limited) entered into a Subscription Agreement.
- The agreement provides for an initial closing of at least $2 million, expected on March 31, 2025.
- Total aggregate gross proceeds from the subscription are capped at $5 million.
- Upon completion of all share sales, Beyond Air Ireland's ownership in NeuroNos will be reduced to approximately 75% (from an initial ~88%).
- A Shareholders Agreement was entered into effective March 31, 2025.
Beyond Air, Inc. announced the resignation of Ron Bentsur from its Board of Directors and disclosed new global distribution agreements for LungFit PH® across four countries.
🚩 Red Flags
- None identified; resignation was explicitly stated as non-dispute related.
📋 Key Facts
- Ron Bentsur resigned from the Board of Directors effective March 14, 2025.
- The company stated Mr. Bentsur's resignation is not due to any disagreement with the Company or its management regarding operations, policies, or practices.
- Beyond Air announced expansion of global distribution channels for LungFit PH® via new agreements in France, Romania, Turkey, and Morocco.
Beyond Air, Inc. entered into an At-The-Market (ATM) equity offering agreement with BTIG, LLC to sell common stock up to a gross sales price of $9,892,518.
🚩 Red Flags
- Potential dilution for existing shareholders through the issuance of new common stock.
- The use of an ATM offering often indicates a need for immediate working capital or cash runway extension.
📋 Key Facts
- Entered into an ATM Equity Offering Sales Agreement with BTIG, LLC on February 14, 2025.
- The agreement allows for the sale of common stock under a previously declared S-3 registration statement (effective Feb 10, 2025).
- Current aggregate gross sales price limit is $9,892,518 due to public float limitations under General Instruction I.B.6 of Form S-3.
- The company has the potential to increase this amount if its public float increases.
- Agent (BTIG, LLC) receives a commission of up to 3% of gross sales proceeds.
Beyond Air, Inc. filed an 8-K to announce the release of its financial results for the fiscal quarter ended December 31, 2024.
📋 Key Facts
- The filing is a standard announcement of quarterly earnings (Item 2.02).
- Reporting period: Fiscal quarter ended December 31, 2024.
- Date of report/event: February 10, 2025.
- The company issued a press release as Exhibit 99.1 to accompany the results.
Beyond Air, Inc. has received a second 180-day compliance period from Nasdaq to address its failure to meet the minimum $1.00 bid price requirement. The company intends to cure this deficiency by August 4, 2025, potentially through a reverse stock split.
🚩 Red Flags
- Continued failure to meet the $1.00 minimum bid price requirement (Nasdaq Rule 5550(a)(2)).
- Explicit mention of a potential reverse stock split as the primary method for compliance.
- Risk of delisting if compliance is not demonstrated by August 4, 2025.
📋 Key Facts
- Nasdaq granted an additional 180-day compliance period until August 4, 2025.
- The initial compliance period expired on February 4, 2025.
- Compliance requires the closing bid price to be at least $1.00 for ten consecutive business days.
- The company has expressed its intention to use a reverse stock split to regain compliance if necessary.
- The company meets other Nasdaq listing requirements including market value of publicly held shares.
Beyond Air, Inc. has dismissed its independent auditor, Marcum LLP, and appointed WithumSmith+Brown, PC as its new successor auditor, effective December 17, 2024.
🚩 Red Flags
- Auditor change (dismissal of Marcum LLP).
- Existing 'going concern' language in previous audit reports (FY ended March 31, 2024) regarding the company's ability to continue operations.
📋 Key Facts
- Dismissal of Marcum LLP by the Audit Committee on December 17, 2024.
- Appointment of WithumSmith+Brown, PC (Withum) as successor auditor for fiscal year ending March 31, 2025.
- The company stated there were no disagreements with Marcum regarding accounting principles or auditing scope.
- Marcum's previous reports included a paragraph regarding substantial doubt about the Company’s ability to continue as a going concern for the fiscal year ended March 31, 2024.
Beyond Air, Inc. reported a regulatory development regarding its majority-owned affiliate, Beyond Cancer, Ltd. The Israeli Ministry of Health has approved the use of Low Volume UNO (LV UNO) in a Phase 1b clinical trial combined with anti-PD-1 therapy.
📋 Key Facts
- Beyond Cancer, Ltd. is a majority-owned affiliate of Beyond Air, Inc.
- The Israeli Ministry of Health approved LV UNO for use in a Phase 1b clinical trial.
- The trial involves the combination of LV UNO with anti-PD-1 therapy.
- Event date: December 3, 2024.
Beyond Air, Inc. announced it has received European CE mark approval for its LungFit PH® system. This regulatory milestone allows the company to market and sell this specific medical device within the European market.
📋 Key Facts
- Received European CE mark approval for the LungFit PH® system on December 2, 2024.
- The announcement was made via a press release issued on December 2, 2024.
Beyond Air, Inc. held its 2025 Annual Meeting where stockholders approved several significant measures, including a massive increase in authorized shares and a one-time stock option repricing for insiders.
🚩 Red Flags
- Significant option repricing: Over 10.5 million options were repriced to $0.54 for insiders (CEO, COO, CFO, and Directors), which is a major red flag indicating significant downward pressure on stock price.
- Massive dilution potential: Authorized shares increased from 100M to 500M (a 5x increase).
- Warrant issuance approval: Approval of share issuances exceeding the 20% Nasdaq threshold suggests heavy use of dilutive financing instruments.
📋 Key Facts
- Stockholders approved the Seventh Amended and Restated 2013 Equity Incentive Plan, increasing reserved shares by 3,000,000.
- The Board executed a one-time repricing of 10,586,473 options for directors, officers, and employees to an exercise price of $0.54 (matching the closing price on Nov 22, 2024).
- Stockholders approved increasing authorized common stock from 100,000,000 to 500,000,000 shares.
- Approval was granted for the issuance of shares underlying warrants in an amount exceeding 20% of outstanding common stock (Nasdaq Rule 5635(d) compliance).
- Marcum LLP was ratified as the independent auditor.
Beyond Air, Inc. filed an 8-K to announce its financial results for the fiscal quarter ended September 30, 2024.
📋 Key Facts
- The filing is a formal announcement of quarterly earnings results.
- The reporting period covered is the fiscal quarter ended September 30, 2024.
- The announcement was made via press release on November 11, 2024.
Beyond Air, Inc. entered into a $11.5 million secured loan agreement with its CEO (Steven Lisi) and a Director (Robert Carey). The deal includes high-interest rates, PIK (payment-in-kind) interest components, and significant equity warrants for the insiders.
🚩 Red Flags
- Related-party transaction involving the CEO and a Director as primary lenders.
- High interest rate (15%) with significant PIK (payment-in-kind) component increasing debt burden.
- Lenders have security interests in substantially all of the Company's assets.
- Significant potential dilution via warrants totaling over 13 million shares at a low exercise price.
📋 Key Facts
- Loan amount: $11,500,000 secured by substantially all of the Company's assets.
- Lenders are CEO Steven Lisi and Director Robert Carey.
- Interest rate: 15% per annum (3% cash / 12% PIK through June 30, 2026; thereafter 15% in cash).
- Repayment mechanism involves a 'Royalty Interest' based on 8% of net sales starting October 1, 2026.
- Warrants issued to Lisi and Cary for a total of 13,182,177 shares at an exercise price of $0.3793 per share.
- Maturity date: October 4, 2034.
Beyond Air, Inc. announced the date for its 2025 Annual Meeting of Stockholders, scheduled for December 9, 2024. The filing also outlines deadlines for stockholder proposals and director nominations.
📋 Key Facts
- The 2025 Annual Meeting of Stockholders is set for December 9, 2024.
- Stockholder proposals under Rule 14a-8 or company bylaws must be received by October 19, 2024.
- Director nominations and other business proposals must also be received by the October 19, 2024 deadline.
Beyond Air, Inc. entered into a binding term sheet for an $11.5 million secured loan from lenders including its CEO and a Director. The deal includes high interest rates, PIK (payment-in-kind) interest, royalty interests on net sales, and equity warrants.
🚩 Red Flags
- Related-party transaction involving the CEO and a Director
- High interest rate (15%) for a micro-cap company
- PIK (Payment-in-Kind) interest structure increases total debt burden over time
- Royalty interest on net sales creates a direct drag on top-line revenue growth
- Asset-backed security: Substantially all assets are pledged to insiders
- Potential significant dilution via warrants at $0.3793 per share
📋 Key Facts
- Principal amount: $11,500,000
- Lenders include CEO Steven Lisi and Director Robert Carey
- Term: 10 years
- Interest rate: 15% per annum (payable in kind through July 2026)
- Royalty component: 8% of net sales quarterly from July 2026 until repayment
- Security: Substantially all Company assets are pledged as collateral
- Warrants: Lenders to receive warrants at an exercise price of $0.3793 per share
- Expected closing/issuance: On or before October 31, 2024
Beyond Air, Inc. entered into a $20.6 million private placement agreement to issue common stock and warrants to accredited investors. The deal includes significant warrant coverage and requires the company to seek shareholder approval for increasing authorized shares.
🚩 Red Flags
- Significant dilution: The issuance of warrants (totaling ~55M potential shares) represents massive potential dilution for existing shareholders.
- Warrant overhang: Common warrants have an exercise price ($0.38) significantly lower than the current offering price ($0.51).
- Liquidated damages: The company faces liquidated damages if it fails to obtain stockholder approval or fails to meet registration statement deadlines.
- Downside protection for investors: Includes a weighted average anti-dilution adjustment formula.
📋 Key Facts
- Aggregate gross proceeds: $20,600,000
- Issuance of 25,000,000 common shares at $0.51 per share
- Issuance of pre-funded warrants for up to 15,392,155 shares at $0.5099 per warrant
- Issuance of common warrants for up to 40,392,155 shares with an exercise price of $0.38
- Expected closing date: September 30, 2024
- Company must hold a meeting within 180 days to seek approval for increasing authorized shares and adjusting warrant terms
- Registration Rights Agreement requires filing a resale registration statement by October 26, 2024
Beyond Air, Inc. received a deficiency notice from Nasdaq because its stock price has been below $1.00 for 30 consecutive business days. The company has until February 4, 2025, to regain compliance or face potential delisting.
🚩 Red Flags
- Nasdaq delisting warning (minimum bid price deficiency).
- Potential for a mandatory reverse stock split to regain compliance.
- Departure of Chief Business Officer/Board Member Amir Avniel (though noted as voluntary).
📋 Key Facts
- Received Nasdaq deficiency notice on August 8, 2024.
- Bid price has been below $1.00 for the last 30 consecutive business days (Nasdaq Listing Rule 5550(a)(2)).
- Compliance deadline is February 4, 2025.
- To regain compliance, stock must close at $1.00+ for 10 consecutive business days before the deadline.
- Company may need to execute a reverse stock split to meet requirements if it enters a second compliance period.
- Amir Avniel is resigning as Chief Business Officer and from the Board effective August 15, 2024.
Beyond Air, Inc. entered into a First Amendment to its existing loan documents with Avenue Capital Management II and related entities. The amendment extends the interest-only period on its senior secured term loans from December 15, 2024, to June 30, 2025.
🚩 Red Flags
- Extension of interest-only period suggests a need for more liquidity before principal repayments begin.
- Issuance of warrants to lenders (equity kicker) often indicates higher risk or desire by lenders for upside in exchange for favorable terms.
- Contingent deferral of payments depends on achieving $40.0 million in product revenue, which is an aggressive target for a micro-cap growth company.
📋 Key Facts
- Amendment extends the expiration of the interest-only period for the $40.0 million loan facility to June 30, 2025.
- Amortization payments are now scheduled to commence on July 1, 2025.
- The company paid an amendment fee of $87,500 and will pay a final $87,500 fee upon maturity or prepayment.
- Issuance of warrants to Avenue Venture Opportunities Fund, L.P. and Avenue Venture Opportunities Fund II, L.P. for up to 100,000 total shares at an exercise price of $1.28 per share.
- The company intends to file a registration statement for the resale of shares issuable upon warrant exercise within 60 days.
Beyond Air, Inc. announced the appointment of David Webster as the new Chief Commercial Officer, effective July 8, 2024.
📋 Key Facts
- Appointment of David Webster as Chief Commercial Officer (CCO).
- Effective date of appointment: July 8, 2024.
- Announcement made via press release on June 13, 2024.
Beyond Air, Inc. completed a registered direct offering of common stock and warrants to institutional and accredited investors. The company raised approximately $14.6 million in net proceeds to fund commercial sales development, research, and working capital.
🚩 Red Flags
- Dilutive offering: Issuance of significant new common stock and warrants will dilute existing shareholders.
- Warrant overhang: The issuance of nearly equal numbers of warrants (1:1 ratio) creates potential future dilution at $2.25 per share.
📋 Key Facts
- Offered 9,638,556 shares of common stock and 9,638,556 warrants at a combined price of $1.66 per share/warrant unit.
- Warrants are exercisable at $2.25 per share for three years from issuance.
- Net proceeds totaled approximately $14.6 million after deducting offering expenses and 7% placement agent fees.
- The offering was conducted via a shelf registration statement (Form S-3) effective February 1, 2022.
- Includes a standstills/no-issuance covenant for 90 days following the closing date of March 22, 2024.
Beyond Air, Inc. held its 2024 Annual Meeting of Stockholders on March 8, 2024. The meeting resulted in the election of seven directors and the approval of an amended equity incentive plan.
🚩 Red Flags
- None identified in this filing.
📋 Key Facts
- Annual Meeting held on March 8, 2024.
- Seven nominees for director were elected to serve until the next annual meeting or successors are qualified.
- Stockholders approved the Sixth Amended and Restated 2013 Equity Incentive Plan, increasing shares reserved by 3,000,000.
- Stockholders ratified the appointment of Marcum LLP as independent registered public accounting firm for FY ending March 31, 2024.
- Quorum was met with 19,946,015 shares represented (out of 35,609,164 total outstanding).
Beyond Air, Inc. entered into an amendment to its At-The-Market (ATM) Equity Offering Sales Agreement to terminate the participation of Oppenheimer & Co. Inc. as a sales agent.
📋 Key Facts
- Amendment No. 1 to the At-The-Market Equity Offering Sales Agreement was executed on February 28, 2024.
- The amendment terminates Oppenheimer & Co. Inc.'s role as an Agent in the program.
- Truist Securities, Inc. remains a sales agent under the agreement.
Beyond Air, Inc. announced its Q3 Fiscal Year 2024 financial results and the transition of its Chief Medical Officer, Jeff Myers, from a full-time employee to a consultant.
🚩 Red Flags
- Departure of a key officer (Chief Medical Officer) can sometimes signal internal shifts or strategic changes, though this is mitigated by the transition to a consulting role.
📋 Key Facts
- Company released Q3 FY2024 financial results on February 12, 2024.
- Chief Medical Officer Jeff Myers is transitioning from his executive role to a consulting position effective around February 16, 2024.
- The transition involves a Consulting Agreement where Dr. Myers will provide non-exclusive services until July 31, 2024.
- The Company will pay Dr. Myers a monthly fee of $16,000 during the consulting period.